Navigation Links
AcelRx Pharmaceuticals Provides Clinical Trial Updates
Date:2/19/2013

he study is designed to assess the ability of sufentanil, delivered through the NanoTab System to control moderate-to-severe post-operative pain over 48 to 72 hours compared to a placebo delivered through the NanoTab System.  The study will also assess the tolerability, safety, and ease of use of the NanoTab System by nurses and patients.  Top-line results are expected in the first quarter of 2013. 
  • A second placebo-controlled Phase 3 trial with the Sufentanil NanoTab PCA System is being conducted at approximately 32 sites in patients following hip or knee replacement surgery.   Targeting enrollment of approximately 400 patients, dosing of the final subject in this study is expected around the end of the first quarter of 2013.  The primary endpoint for both the abdominal and orthopedic placebo-controlled Phase 3 studies is the sum of pain intensity difference to baseline (SPID) over 48 hours. Top-line results should be available for the orthopedic study during the second quarter of 2013.
  • Dosing of the last patient in a Phase 2, placebo-controlled, dose-finding study of the Company's ARX-04 sufentanil NanoTab product has completed.  This study, which began in November 2012, enrolled 101 patients following bunionectomy surgery, randomized into one of three groups: 20 mcg sufentanil NanoTab, 30 mcg sufentanil NanoTab or placebo.  Each dose was administered by healthcare personnel, as requested by the patient, up to a maximum of one dose every hour.  The study is designed to evaluate the ability of sufentanil NanoTabs to manage moderate-to-severe acute pain over the first 12 hours following bunionectomy surgery.  ARX-04 is a sublingual sufentanil product candidate designed to provide a non-invasive, fast-onset treatment of patients with moderate-to-sever acute pain, both on the battlefield and in civilian settings of trauma or injury.  AcelRx is conducting the study at two sites with funding
    '/>"/>

  • SOURCE AcelRx Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4

    Related medicine technology :

    1. AcelRx Appoints Adrian Adams to Board of Directors as Chairman
    2. AcelRx Pharmaceuticals Announces Pricing of Public Offering of Common Stock
    3. AcelRx Pharmaceuticals Announces Proposed Public Offering Of Common Stock
    4. AcelRx Pharmaceuticals to Present at the Piper Jaffray 24th Annual Healthcare Conference
    5. AcelRx Announces Achievement of the Primary End-Point in Phase 3 Comparative Study Involving the Sufentanil NanoTab PCA System and Plans to Hold a Conference Call and Webcast Tomorrow to Discuss Top-Line Results
    6. AcelRx Pharmaceuticals Reports Third Quarter 2012 Financial Results
    7. AcelRx Pharmaceuticals Doses the First Patients in ARX-04 Phase 2 Clinical Study
    8. AcelRx Pharmaceuticals to Hold Third Quarter 2012 Financial Results Conference Call and Webcast on November 6, 2012
    9. AcelRx Pharmaceuticals Hires Mike A. Royal, M.D. as Chief, Clinical Affairs
    10. AcelRx Pharmaceuticals to Present at the UBS Global Life Sciences Conference
    11. AcelRx Pharmaceuticals Receives Fourth and Fifth U.S. Patents for Small-Volume Oral Transmucosal Dosage Forms
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/1/2015)... SPRINGDALE, Ark. , Sept. 1, 2015 NOWDiagnostics Inc., ... completed its acquisition of ZBx Corporation of Canada ... to its vision of a world where people have ... NOWDiagnostics manufactures and sells a line of unique blood-based ... simple-to-use, highly accurate tests for a variety of ailments ...
    (Date:9/1/2015)... 1, 2015 UT Southwestern Medical Center President ... members joined U.S. Representatives Michael C. Burgess , ... discussion on the 21 st Century Cures Act, ... considered by the United States ... Academy of Sciences members, department chairs, center directors, and ...
    (Date:9/1/2015)... Sept. 1, 2015  Results from an interim analysis ... that 5g of idarucizumab enabled emergency surgery to ... treated with dabigatran (Pradaxa ® dabigatran etexilate ... effect of dabigatran enabled patients to be urgently ... of 1.7 hours between administration of idarucizumab and ...
    Breaking Medicine Technology:NOWDiagnostics Inc. Acquires Canada's ZBx Corporation 2NOWDiagnostics Inc. Acquires Canada's ZBx Corporation 3U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 2U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 3U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 4U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 5New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 2New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 3New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 4New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 5New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 6New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 7New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 8New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 9
    ... in wake of AHA-presented data , ... a clinical trial suggesting rosuvastatin may lower the cardiovascular risk ... statin use in older adults, according to a national poll ... the online poll conducted by medical news site MedPage Today ...
    ... FRANCISCO, Calif., Nov. 25 Poniard,Pharmaceuticals, Inc. (Nasdaq: ... on,innovative oncology therapies, announced today that it will ... in order to allow,the Company to focus its ... product candidate, and to support the initial commercialization ...
    Cached Medicine Technology:Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows 2Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows 3Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin 2Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin 3
    (Date:9/1/2015)... ... September 01, 2015 , ... ... pleased to announce their partnership with Apex Physical Therapy (Apex) is ... continue to provide kind, compassionate, and empathetic care to local residents from their ...
    (Date:9/1/2015)... San Diego, CA (PRWEB) , ... September 01, 2015 , ... ... with Bellus Academy will present “The Beauty Behind the Fashion” on Thursday, Oct. ... San Diego® (FWSD), will shine the spotlight on the collaboration between fashion and professional ...
    (Date:9/1/2015)... ... 01, 2015 , ... Horizon Blue Cross Blue Shield of New Jersey (BCBSNJ) ... the LATINA Style 50 Report that recognizes companies that provide the best career opportunities ... BCBSNJ climbs from number 24 to 21 of the 50 Best Companies for Latinas. ...
    (Date:9/1/2015)... Rolling Meadows, Ill. (PRWEB) , ... September 01, ... ... medical procedures done by members of the American Society for Dermatologic Surgery, according ... case. , The 2015 ASDS Consumer Survey on Cosmetic Dermatologic Procedures – which ...
    (Date:9/1/2015)... London, UK (PRWEB) , ... September 01, 2015 ... ... of a vacuum that creates negative pressure inside a wound to remove exudates, ... market for treatment devices (comprising portable devices, stand-alone devices, disposable devices, and canisters, ...
    Breaking Medicine News(10 mins):Health News:ProRehab Physical Therapy Partnership with Apex Physical Therapy Now Official 2Health News:ProRehab Physical Therapy Partnership with Apex Physical Therapy Now Official 3Health News:Celebrity Hairstylist Ted Gibson Explores Fusion of Fashion and Beauty at “Beauty Behind the Fashion” at Fashion Week San Diego Proceeds to benefit THIRST Project 2Health News:Celebrity Hairstylist Ted Gibson Explores Fusion of Fashion and Beauty at “Beauty Behind the Fashion” at Fashion Week San Diego Proceeds to benefit THIRST Project 3Health News:Horizon Blue Cross Blue Shield of New Jersey Named One of the 50 Best Companies for Latinas by Latina Style Magazine 2Health News:Horizon Blue Cross Blue Shield of New Jersey Named One of the 50 Best Companies for Latinas by Latina Style Magazine 3Health News:Survey: Consumers Prefer ASDS Members 2Health News:Survey: Consumers Prefer ASDS Members 3Health News:World Negative Pressure Wound Therapy Market Assessed by GlobalData in In-demand Report Published at MarketPublishers.com 2Health News:World Negative Pressure Wound Therapy Market Assessed by GlobalData in In-demand Report Published at MarketPublishers.com 3
    ... N.J., July 23 VS Holdings, Inc. (the "Company"), the parent of ... statement on Form S-1 with the U.S. Securities and Exchange Commission relating ... consummation of the offering, the Company will be renamed Vitamin Shoppe, Inc. ... are expected to be offered by the Company. , ...
    ... , Diverse Donors Make the Difference , ... Awareness Day is August 1, and New York Blood Center (NYBC) and its ... on the community to help us meet the great need for blood from ... Minority Donor Awareness Day emphasized minority organ and tissue donation, but blood donation ...
    ... , , Partnership to ... , ARLINGTON, Va., July 23 Health ... Clinton Climate Initiative (CCI), a project of the William J. Clinton ... their environmental impact, particularly in the area of carbon reduction. ...
    ... colitis, but oily fish could be protective, study shows, , ... a common polyunsaturated fatty acid could be a contributing factor ... colitis, researchers say. , In a new study, participants ... than double the chance of developing the painful inflammation and ...
    ... by researchers at the Ohio State University Comprehensive Cancer ... prostate tumors gain the ability to grow without need ... an advanced and currently incurable stage of prostate cancer. ... of the journal Cell , focuses on androgen ...
    ... new studies reveal a way to increase the body,s appetite for ... (AML), a form of cancer with a particularly poor survival rate. ... cells that sends a "don,t eat me" signal to the macrophage ... to the reports in the July 24th issue of the journal ...
    Cached Medicine News:Health News:Vitamin Shoppe Files Registration Statement for Initial Public Offering of Common Stock 2Health News:Vitamin Shoppe Files Registration Statement for Initial Public Offering of Common Stock 3Health News:The Gift of Life Flows Through Your Veins! 2Health News:The Gift of Life Flows Through Your Veins! 3Health News:Health Care Without Harm Partners With Clinton Climate Initiative to Help Hospitals and Healthcare Facilities Reduce Environmental Impact 2Health News:Health Care Without Harm Partners With Clinton Climate Initiative to Help Hospitals and Healthcare Facilities Reduce Environmental Impact 3Health News:Fatty Acids in Diet Linked to Bowel Disease Risk 2Health News:Scientists discover key event in prostate cancer progression 2Health News:Stripping leukemia-initiating cells of their 'invisibility cloak' 2
    RIA kit for the quantitative determination of autoantibodies to thyroid peroxidase (TPO) in serum....
    For the quantitative determination of Estradiol (E2) concentration in human serum or plasma....
    ... Estradiol (E2) concentration in human serum or plasma. ... a phenolic A ring. This steroid hormone ... is the most potent natural Estrogen, produced mainly ... by the adrenal cortex, and the male testes. ...
    ... (cTnI) has been useful in the differential ... (ED) with chest pain. 18-20 ... levels of sensitive and specific biomarkers, such ... creatine kinase (CK-MB), and myoglobin, are increased ...
    Medicine Products: